Diffuse large B-cell lymphoma: An institutional analysis.

South Asian J Cancer 2018 Jul-Sep;7(3):200-202

Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma. We conducted a retrospective study to analyze the clinicopathological characteristics, cell of origin, response to therapy, and the outcome of patients with DLBCL.

Materials And Methods: This was a retrospective study which included all patients with DLBCL registered at our center, between May 1, 2013, and July 31, 2015. The data regarding demography, clinical presentation, histopathology, stage, prognostic index, treatment, and treatment-related outcome were collected from prospectively maintained clinical case records of the patients.

Results: In the study, we included 267 patients. The median age is 49 (20-81) years with male: female ratio of 2:1. B symptoms were seen in 124 (45%) of patients. Early Stages (I and II) were seen in 130 (52%) patients, while advanced Stages (III and 1V) were seen in 119 (48%) patients. Bulky disease (>7.5 cm) was seen in 30% of cases, and bone marrow was involved in 12%. Extranodal involvement is present in 35% of cases. Cell of origin data was available in 160 (60%) of cases, of which 88 (55%) were germinal center and 72 (45%) were activated B cell in origin. The distribution according to the international prognostic index (IPI) was as follows: low risk 40%, intermediate risk 45%, and high risk in 15%. Rituximab was used in 45% of cases. The overall response rate was 84% with a complete response (CR) rate of 70.5%. The CR rates were better with RCHOP compared with CHOP (77% vs. 61.5%, = 0.001) and good-risk IPI (83.3% vs. 65.2%, < 0.001) compared with intermediate- and high-risk IPI. Median follow-up period was 24 months, and 2-year event-free survival (EFS) was 70%. The presence of B symptoms, high IPI, failure to attain CR, poor PS, and nonrituximab-based chemotherapy were significantly associated with lower EFS.

Conclusions: This is the first study from India, which investigated the impact of chemotherapy with or without rituximab in context of cell of origin. Adding rituximab to CHOP showed better response rate and EFS irrespective of cell of origin.

Download full-text PDF

Source
http://dx.doi.org/10.4103/sajc.sajc_65_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069326PMC
August 2018
3 Reads

Publication Analysis

Top Keywords

cell origin
20
response rate
12
retrospective study
8
b-cell lymphoma
8
study included
8
diffuse large
8
large b-cell
8
patients
6
cell
5
origin
5
2-year event-free
4
30% cases
4
cases bone
4
disease >75
4
bulky disease
4
event-free survival
4
>75 30%
4
cases
4
bone marrow
4
cases cell
4

Similar Publications